A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.

Hilary Glen, Sumanta K. Pal, Daniel Yick Chin Heng et al.|Journal of Clinical Oncology|2018

Cited by 4